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Abstract: Aberrant profiles of pre-mRNA splicing are frequently observed in cancer. At the molecular
level, an altered profile results from a complex interplay between chromatin modifications, the
transcriptional elongation rate of RNA polymerase, and effective binding of the spliceosome to the
generated transcripts. Key players in this interplay are regulatory splicing factors (SFs) that bind to
gene-specific splice-regulatory sequence elements. Although mutations in genes of some SFs were
described, a major driver of aberrant splicing profiles is oncogenic signal transduction pathways.
Signaling can affect either the transcriptional expression levels of SFs or the post-translational
modification of SF proteins, and both modulate the ratio of nuclear versus cytoplasmic SFs in a given
cell. Here, we will review currently known mechanisms by which cancer cell signaling, including
the mitogen-activated protein kinases (MAPK), phosphatidylinositol 3 (PI3)-kinase pathway (PI3K)
and wingless (Wnt) pathways but also signals from the tumor microenvironment, modulate the
activity or subcellular localization of the Ser/Arg rich (SR) proteins and heterogeneous nuclear
ribonucleoproteins (hnRNPs) families of SFs.
Keywords: alternative splicing; cancer cell; genetic program; signaling pathway; tumorigenesis;
tumor microenvironment
1. Introduction
Transcription of a protein-coding gene in human cells generates a primary transcript, the
pre-mRNA that still contains intervening intronic sequences, which in general are co-transcriptionally
removed during the process of mRNA splicing. This process is catalyzed by the spliceosome,
a macromolecular machinery involving five small nuclear ribonucleoprotein particles (U1, U2, U4,
U5, and U6 snRNP), which recognizes conserved nucleotide sequences around each exon-intron
junction [1,2]. Additional sequence elements in exons or introns can act as enhancers or silencers, and
mediate the binding of splicing factors that either promote or inhibit productive recognition of a given
exon by the spliceosome. Two main families of such splicing factors are the Ser/Arg rich (SR) proteins
and the heterogeneous nuclear ribonucleoproteins (hnRNPs), which often act antagonistically and
thus allow regulation of exon recognition through a combinatorial mode of operation.
Eukaryotic cells use this processing step to increase their diversity in gene expression by
generating various mRNA isoforms from the same pre-mRNA through alternative splicing. The era
of genome-wide high-throughput sequencing technologies has revealed that over 90% of human
genes can undergo alternative splicing [3–7]. Most frequently observed is the inclusion or skipping
of individual exons, but other variations include the use of alternative 5′ or 3′ splice sites within
exons, intron retention, or alternative terminal exons with distinct polyadenylation sites. In addition,
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the usage of alternative promoters can contribute with different first exons to pre-mRNAs transcribed
from the same gene [8].
From a functional point of view, an alternative spliced transcript can have two effects: (i) either
it is translated into a protein with different functional properties [9–11], (ii) or it regulates the
respective gene’s expression level. Examples are the degradation of nuclear-retained intron-containing
transcripts [12], the degradation of premature stop codon containing alternative transcripts by the
nonsense mediated decay pathway [13,14], or the modulation of mRNA stability or translation efficacy
by loss of microRNA (miRNA) binding sites in alternative 3′-untranslated regions [15,16].
Different tissues share the same genome but generate different profiles of alternative splice
variants as part of their gene expression programs [17–20]. Since tumor development is also
characterized by gene expression program changes, aberrant profiles of alternative splicing were
consistently reported [21–23]. In contrast to genetic diseases, where a disease-causing gene can suffer a
mutation that interferes with the normal splicing process of its mRNA, aberrant profiles observed in
tumors mostly reflect the selection of endogenous alternative splicing variants with different functional
properties that allow the malignant progression of initiated tumor cells. Selected functions relate,
for example, to sustained proliferation, evasion of apoptosis, metabolic adaptation, or angiogenesis.
Thus, the observed changes are not simply bystander effects of altered cellular programs but contribute
specifically to tumor progression. Some well-studied examples of such alternative splicing variants are
described in this review and have been summarized in Supplementary Table S1.
The aberrant splicing patterns observed in cancer can originate from different molecular
mechanisms. Whereas mutations in splicing-regulatory sequences of target genes are frequently
detected in genetic diseases, this does not seem to be the major event during sporadic tumor
development. It should, however, be mentioned that the application of next-generation sequencing
technologies has detected cases with gain-of-function point-mutations in splicing factor genes, mainly
the constitutive spliceosome factors, splicing factor 3b subunit 1 (SF3B1) and U2 small nuclear RNA
auxiliary factor 1 (U2AF1), in myeloid cell malignancies and rare cases of breast or lung cancer [24–26].
Another target are inactivating mutations in zinc finger CCCH-type, RNA binding motif and
serine/arginine rich 2 (ZRSR2) gene encoding a component of the minor U12 dependent-spliceosome
that result in a variety of alternative splicing variants related to oncogenic signaling pathways [27].
Thus, it cannot be excluded that certain mutations may exert a driver effect in tumorigenesis by altering
signaling pathway dynamics.
More consistently reported was that tumors display changes in splicing factor expression
levels [28–31]. These changes disturb the balance between cooperating or antagonizing splicing
factors in genome-wide splicing decisions, and can exert a clear oncogenic effect, as documented for
splicing factor serine and arginine rich splicing factor 1 (SRSF1) [32].
Two aspects need to be considered in this respect: transcriptional changes in the expression
of splicing factor genes and the post-translational modification of the corresponding splicing factor
proteins. The genetic alterations underlying the observed changes in splicing factor expression
in tumors remain mostly unclear; however, recent genome-wide analyses have emphasized the
existence of a ‘dark matter’ in cancer genomes that requires better characterization, namely the
potential cancer-driving mutations in non-coding regions that may affect gene regulation steps such
as transcription, splicing, mRNA stability, or translation [33]. Another mechanism disturbing the
balance is the post-translational modification of splicing factor proteins, with consequences for their
activity, subcellular localization, or proteasomal degradation. Significant progress has been made in
understanding these more dynamic aspects of splicing regulation. Therefore, this review will focus on
the deregulation of splicing profiles in tumor cells in consequence of either oncogene-driven signaling
or signals received from the tumor microenvironment.
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2. Deregulation of Alternative Splicing by Oncogene-Driven Signaling
Our understanding of tumor cell biology is intimately connected to the determination of
certain hallmark capabilities, which include self-sufficiency in proliferative signals and evasion of
growth suppressing mechanisms [34]. Most of these capabilities are accomplished through signaling
pathways that are typically composed of a signal-perceiving receptor, which transmits successful
ligand binding into a chain of biochemical events among a group of molecules inside the cell
to control a cell function or response. The biochemical events involve protein interactions and
post-translational protein modifications, most commonly protein phosphorylation catalyzed by protein
kinases. Abnormal activation of such signaling pathways is common in cancer and provides attractive
targets for drug development to block the growth and survival of malignant cells [35].
Abnormal activation originates in the cancer cell from gene mutations that either result in growth
factor receptor activation in the absence of their ligand, or activate downstream components of
growth factor receptor-stimulated signaling cascades, or eliminate factors conferring negative feedback
regulation. These are cancer cell intrinsic alterations and were found to clearly affect alternative
splicing decisions, as will be described in the following sections.
2.1. Oncogenic Stimulation of the RAS/RAF/ERK Pathway
Activation of the small GTPase RAS with subsequent stimulation of a cascade of three
mitogen-activated protein kinases (MAPK, namely RAF, MEK and ERK), is a key event in the
majority of epithelia cell-derived tumors. Oncogenic Kirsten rat sarcoma viral (KRAS) mutations
that activate the pathway in the absence of ligand binding to plasma membrane receptor tyrosine
kinases are a hallmark of many epithelial cancers. Bioinformatic analysis of transcriptomic data
obtained from colon adenocarcinoma or lung squamous cell carcinoma revealed that the presence of
oncogenic KRAS correlated with a regulatory network of functional splicing aberrations. The network
involved increased levels of the transcription factors ETS transcription factor (ELK1) and avian
myelocytomatosis viral oncogene homolog (MYC), which both together then induced expression
of the alternative splicing factor polypyrimidine tract-binding protein 1 (PTBP1). Increased PTBP1
levels associated with a shift in the alternative splicing of transcripts encoding the small GTPase
RAC1, adaptor protein NUMB, and Pyruvate Kinase (PKM), all of which have an experimentally
documented role in tumorigenesis [36]. The PTBP1 overexpression was detected in colorectal cancer
tissues when compared with corresponding normal mucosa, and correlated with increased c-MYC
expression levels and altered ratios between the two alternative PKM variants, PKM2 and PKM1 [37],
which contain the mutually exclusive exons 10 or 9, respectively, and differ in enzyme kinetics.
In cancer cells, PKM2 expression promotes the accumulation of upstream glycolytic intermediates to
fuel the anabolic metabolism.
Besides transcriptional stimulation, the activation of the MAPK extracellular signal regulated
kinase (ERK) downstream of RAS can also lead to the direction of the phosphorylation of splicing
factors. For example, the inclusion of exon v5 into the cell surface tumor marker clusters of
differentiation 44 (CD44) enhances malignancy and invasiveness of some tumors, and is regulated by
splicing factor signal transduction and activation of RNA metabolism 68 (SAM68). ERK phosphorylates
SAM68 in T-lymphoma cells [38,39], enhancing its RNA binding activity. The same pathway was
described in colorectal cancer cells and leads to binding of phospho-SAM68 to the 3′UTR of the SRSF1
transcript [40]. The binding promotes retention of an intron required for production of full-length
SRSF1 transcript and avoids an alternative splicing event that would downregulate SRSF1 transcripts
through the nonsense-mediated mRNA decay pathway. Thus, ERK activation results in an increased
level of SRSF1 protein and corresponding switch in the splicing profile, e.g., of the RON gene transcripts
(see Section 3.1.1).
Furthermore, ERK2 phosphorylates splicing factor SPF45 (RBM 17) in cells carrying oncogenic
Harvey rat sarcoma viral oncogene homolog (HRAS)G12V or B-isoform of rapidly accelerated
fibrosarcoma (BRAF)V600E mutations. Phosphorylation of SPF45 led to the inclusion of the alternative
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extra domain I (ED-I) region into fibronectin transcripts, which increases the ability to promote cell
cycle progression and wound healing, but also to exon 6 exclusion from First apoptosis signal (FAS)
mRNA generating a variant that inhibits FAS-mediated cell death [41]. Interestingly, SPF45 was shown
to be also phosphorylated by Jun N-terminal kinase 1 (JNK1) and p38α MAPK, suggesting it can be
modulated through multiple pathways.
Another mechanism known to affect alternative splicing is nucleocytoplasmic distribution of
splicing factors. In colon cancers carrying an activating mutation in the RAS-interacting kinase
BRAF, RANBP2 was found to be upregulated [42]. This protein regulates nucleocytoplasmic
transport of phosphorylated pre-mRNA processing factors as well as their speckled intra-nuclear
distribution, and RANBP2 overexpression affected alternative splicing patterns, including the
transcripts encoding CDC-like kinase (CLK) and the anti-apoptotic splice variant BCL-x(L) of apoptosis
regulator BCL2L1 [43].
Interestingly, a recent paper suggested that hnRNPA2 up-regulation in hepatocellular carcinoma
induces an alternative splicing switch that downregulates a dominant-negative isoform of A-RAF,
leading to activation of the RAF-MEK-ERK pathway and cellular transformation [44]. This example
highlights that the generation of certain alternative splicing variants can also shape cancer cell signaling,
for example by exploiting feedback mechanisms that further sustain tumor cell survival.
2.2. Stimulation of the PI3K/AKT Pathway
The phosphatidylinositol 3 (PI3)-kinase pathway (PI3K) is another key pathway involved in
cell survival and escape from apoptosis in a significant number of solid tumors. It involves the
phosphorylation of phospholipid components of cell membranes that then serve as docking sites
for the recruitment of proteins to the plasma membrane, and subsequent activation of signaling
cascades. This pathway is mainly activated by mutation or amplification of the PI3K catalytic
subunit α (PIK3CA) gene, or inactivation of the antagonistic phosphatase and tensin homolog (PTEN)
phosphatase gene [45,46]. The effector following activation of this pathway is protein kinase v-akt
murine thymoma viral oncogene homolog (AKT), which triggers the phosphorylation of splicing
regulatory proteins. For example, AKT was shown to phosphorylate SRSF1 and SRSF7 proteins in vitro
when immunoprecipitated from HEK293T or COS-7 cells [47], and overexpression of constitutively
active AKT increased alternative splicing of a cell cycle promoting fibronectin transcript. A subsequent
study raised the possibility that the described abilities of immunopurified AKT to phosphorylate SR
proteins may be caused by associated SRSF protein kinase (SRPKs), because in epidermal growth
factor (EGF)-stimulated HEK293T cells AKT1 promoted SRPK1 and SRPK2 autophosphorylation and
translocation to the nucleus, with corresponding changes in alternative splicing of an Adenovirus
early region 1A (E1A) minigene reporter [48]. On the other hand, another arginine-serine rich (RS)
domain-containing protein, the Lamin B receptor, was shown to be directly phosphorylated by both
AKT1 and SRPK1 [49]. The SRPK1 activity is important for binding SR proteins with high affinity in
the cytosol and progressively phosphorylating 10–12 serine residues in the N-terminal region of the
RS domain (RS1). This modification is required for nuclear import of SR proteins and their typical
localization in speckles [50,51].
Similar splicing modulation was found for caspase-9 (Casp-9) in lung cancer cells, in which
activated AKT phosphorylated SRSF1, thereby leading to exclusion of an exon 3,4,5,6 cassette and
generation of the anti-apoptotic Casp-9b isoform [52]. In parallel, AKT-mediated phosphorylation of
hnRNPL induced its binding to a splice silencer element in Casp-9 pre-mRNA, further enhancing the
exclusion of the above mentioned four-exon cassette [53,54].
The PI3K/AKT pathway is also known to activate the mammalian target of rapamycin complex 1
(mTORC1), a key regulator of cell metabolism and growth. It controls the rate of protein synthesis via
the eukaryotic translation initiation factor 4E-binding protein (4E-BP) and ribosomal protein S6 kinase
(S6K), and is inhibited by the anti-cancer drug rapamycin [55]. Recent data revealed an mTORC1-S6K1
pathway leading to phosphorylation of kinase SRPK2, which translocates to the nucleus and activates
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SR protein binding to the U1-70K spliceosome component to promote splicing of lipogenesis-related
transcripts to fuel cancer metabolism [56].
In hepatocellular carcinoma, RAS signaling led to AKT activation and subsequent
SRSF1-dependent splicing of the SV1 isoform of Krüppel-like factor 6 (KLF6), a cytoplasmic inactive
variant of this tumor-suppressing transcription factor [57]. Also, phosphorylation of SRSF5 by AKT2
has been shown to regulate exon inclusion in the protein kinase C (PKC) βII isoform [58,59], which is
associated with colon carcinogenesis [60].
2.3. Stimulation of the Wnt Pathway
The wingless (Wnt) signaling is important in regulating development and stemness, and its
tight association with many cancer types has been well studied in colorectal cancer (CRC) [61].
Upon Wnt ligand binding, the transcriptional co-activator β-catenin is protected from proteolytic
degradation, which is otherwise triggered by a multi-protein destruction complex comprising Axin,
Adenomatous polyposis coli (APC) protein and protein kinase glycogen synthase 3β (GSK3β).
Crosstalk between Wnt signaling and alternative RNA splicing in CRC includes effects on the
expression of Ras-related C3 botulinum toxin substrate 1b (RAC1b), an alternatively spliced variant
promoting nuclear factor of κ light polypeptide gene enhancer in B cells (NF-κB) activation and tumor
cell survival. Activated β-catenin signaling directly increased the transcription of the SRSF3 gene [62].
One described effect of SRSF3 is the negative regulation of RAC1 exon 3b inclusion and thus of RAC1b
levels [63] that are upregulated in BRAF-mutant CRC [64].
By contrast, inclusion of RAC1 exon 3b was shown to require SRSF1 in colorectal cells [63] and
more recent studies revealed that protein kinases SRPK1 and GSK3β act upstream of SRSF1 [65].
SRPK1 and SRSF1 also mediated alternative splicing of two mutually exclusive exons 4A and 4B
of the solute carrier family 39 (zinc transporter) member 14 (SLC39A14) gene, encoding a metal ion
transporter. In colorectal tumors, the Wnt pathway induced expression of a high-affinity variant [66].
GSK3β is part of the canonical Wnt signaling pathway, but can also be regulated through an inhibitory
phosphorylation by AKT. Surprisingly, this mechanism is apparently not used for regulating RAC1b
in colorectal cells because only GSK3β, but not AKT depletion, affected RAC1b transcript levels [65].
A role for GSK3β in regulating splicing has also been reported through direct phosphorylation of
splicing factors such as SRSF2 [67] or PTB-associated splicing factor (PSF) [68], and can further be
deduced from the lack of phosphorylation of RNA splicing factors (including SRSF9, Serine and
arginine repetitive matrix 1 (SRRM1); SRRM2; Transformer 2 β homolog (TRA2B); SRSF10; and
CUGBP elay-like family member 1 (CELF1)) in GSK3 knock-out cells, which was associated with
194 splicing differences in 188 genes [69].
Another important splicing factor controlled by the Wnt signaling in colon cancer cells is PTBP1.
Its gene expression is controlled by a transcriptional complex formed by β-catenin, T Cell-specific
transcription factor/Lymphoid enhancer-binding factor (TCF/LEF) and nuclear phospho-PKM2
(pSer37), a phosphorylation performed by ERK in response to KRAS activation [70].
2.4. Other Pathways Activated in Proliferating Cells
The soluble second messenger cyclic adenosine monophosphate (cAMP) is generated following
activation of G-protein-coupled membrane receptors by hormones or local mediators and activates
protein kinase A (PKA), which is involved in the regulation of cell proliferation during the onset and
progression of various tumors [71]. Splicing regulator PTBP1 was found to be directly phosphorylated
on Ser-16 by PKA, resulting in the accumulation of PTBP1 in the cytoplasm [72].
Another PKA regulated protein is transcription factor Wilms tumor 1 (WT1) that binds to and
represses the promoter of the SRPK1 gene through a specific WT1 binding site. Phosphorylation
of WT1 on Ser 365 and 393 blocks its DNA binding and results in its cytoplasmic retention [73,74].
In the absence of functional WT1, SRPK1 expression and subsequent hyperphosphorylation of SRSF1
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increased, promoting, for example, the expression of the pro-angiogenic vascular endothelial growth
factor (VEGF) splice variant VEGF165 [75].
Casein kinase 2 (CK2) is a further protein kinase involved in the regulation of SRPK1.
Biochemical evidence in testis extracts showed phosphorylation of SRPK1 by CK2 at Ser51 and
Ser555, increasing its enzymatic activity in vitro [76]. Elevated levels of protein kinase CK2 have long
been associated with increased cell growth and proliferation both in normal and cancer cells [77].
Calcium signaling is yet another pathway contributing to tumor progression, mainly via metabolic
adaptation of tumor cells or their evasion from apoptosis [78,79]. An influx of Ca2+ ions was shown
to trigger activation of calcium/calmodulin-dependent protein kinase type IV (CaMKIV), which
phosphorylates the splicing repressor hnRNPL and enhances its binding to an RNA element called
the CaRRE motif near the 3′ splice site of several target gene transcripts. This modulates alternative
splicing events, including the skipping of the stress axis regulated exon (STREX) of potassium channel
SLO1 that confers higher channel activity [80,81].
3. Deregulation of Alternative Splicing by Tumor Microenvironment-Derived Signaling
Although cancer cells accumulate mutations and genetic changes during tumor progression, recent
advances have suggested that this alone may not be sufficient to drive cancer as a clinical disease [82].
The tissue microenvironment provides crucial signaling to initiated tumor cells. When intact, it
can inhibit the growth of existing malignant cells and maintain tissue architecture. On the contrary,
a microenvironment characterized by chronic inflammation, oxidative stress or immune-suppression
will promote tumor cell expansion. A dynamic and reciprocal interaction between the neoplastic and
stromal cells exists along the stages of tumorigenesis. In the following, microenvironmental stimuli
such as stromal cell-derived soluble factors or the extracellular matrix are reviewed that were identified
to induce changes in alternative splicing of epithelial tumor cells.
3.1. Soluble Factors
3.1.1. Growth Factor Signaling
Under physiological conditions, cells receive fate-determining signals from their tissue
surroundings, primarily in the form of polypeptide growth factors. Although tumor formation is
generally initiated by oncogenic mutations, growth factors are major regulators of tumor progression,
including clonal expansion, invasion across tissue barriers, angiogenesis, and colonization of distant
niches [83]. Growth factors can be secreted by other cell types from the tumor microenvironment, are
released upon proteolytic degradation of the extracellular matrix, or result from autocrine production
by the cancer cells themselves. In addition, growth factor receptor signaling can result from the
presence of activating receptor mutations.
A study in EGF-stimulated cells identified that AKT1 promoted SRPK1 and SRPK2
autophosphorylation and translocation to the nucleus, with corresponding changes in alternative
splicing of an E1A minigene reporter. Under these conditions, at least 398 changes in alternative
splicing of endogenous transcripts were determined and of these about 75% were mediated by SRPK1
and SRPK2 [48,84]. Growth factor stimulation of mouse mammary epithelial cells also activated the
PI3K/AKT pathway to regulate SRSF7 and SRSF1 levels, and promoted inclusion of the fibronectin
ED-I exon [47], which increases the ability to promote cell cycle progression and wound healing.
A similar regulation was found for Casp-9 in lung cancer cells in which activated AKT phosphorylates
SRSF1, thereby inhibiting synthesis of anti-apoptotic Casp-9b isoform [52].
Hepatocyte growth factor (HGF) enhanced alternative splicing of a tumor-promoting variant of
the tumor suppressor KLF6 by decreasing the levels of SRSF3 and, in consequence, also the levels of
SRSF1 because the lack of SRSF3 triggers an alternative splicing into a non-functional SRSF1 transcript
degraded through the nonsense-mediated mRNA decay pathway [85].
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Signaling through transforming growth factor β (TGF-β) during tumor progression causes
epithelial-mesenchymal transition and is causally linked to metastasis. TGF-β was shown to induce
widespread alterations in splicing affecting over 3600 genes. One major mechanism involved the
transcriptional downregulation of the epithelial splicing regulatory proteins (ESRPs) through zinc
finger E-box binding homeobox 1 (ZEB1) and ZEB2 transcriptional suppressor proteins [86]. The ESRPs
regulate a network of transcripts that switch splicing during the epithelial-mesenchymal transition
and have roles such as organization of actin cytoskeleton, cell to cell adhesion, cell polarity, and
migration [87]. Reported examples were CD44, fibroblast growth factor receptor (FGFR), p120 catenin
(CTNND1) [86] and RAC1b [88].
Interestingly, the TGF-β receptor I (TβRI) undergoes ligand-dependent nuclear translocation in
cancer cells and forms a complex with several nuclear proteins implicated in posttranscriptional RNA
processing, including splicing regulator hnRNPA1 [89]. This specifically induced alternative splicing
events, including the generation of a soluble Epidermal growth factor receptor (EGFR) isoform.
The Insulin Growth Factor (IGF) receptor activates SRPK1 to switch between two VEGF splicing
isoforms in regulating the balance of pro- and anti-angiogenic VEGF isoforms [75,90]. The same
receptor can also activate the RAS-ERK signaling pathway and upregulate INSR (insulin receptor) exon
11 inclusion through the splicing factor SRSF1 in pancreatic β cells [91], or induces alternative splicing
of PKCβII mRNA in L6 cells via the PI3K signaling pathway and phosphorylation state of SRSF5 [92].
In colorectal cancer cells, soluble factors of epithelial origin were shown to induce a constitutively
active splice variant of the macrophage stimulating 1 receptor (MST1R) gene encoding the receptor
tyrosine kinase named RON [40]. The pathway involves activation of ERK to phosphorylate SAM68,
which then promotes stable transcript levels of SRSF1, the splice-enhancing factor that promotes
skipping of RON exon 11. This change in SRSF1 expression counteracts the antagonistic binding of
hnRNPA1 to a nearby silencer element [93] and favors the generation of the active RON variant with
signaling properties promoting the epithelial-mesenchymal transition [94].
3.1.2. Immune Cell or Inflammation-Derived Signals
The tumor microenvironment generally contains immune cells that release cytokines and these are
perceived both, by other immune cells and tumor cells of epithelial origin. The corresponding effects
on alternative splicing have yet been poorly explored. In one study, breast epithelial cells responded
to the release of interferon γ (IFN-γ) by immune cells with Janus Kinase/Signal transducer and
activator of transcription (JAK/STAT) pathway-mediated induction of Interferon regulatory factor-1
(IRF-1) expression. IRF-1 is a master regulator of IFN-γ-induced gene transcription, but transcriptome
sequencing revealed that IRF-1 also affected alternative splicing of various genes involved in the
regulation of growth and differentiation. For example, the carcinoembryonic antigen-related cell
adhesion molecule-1 (CEACAM1) generates a long and pro-invasive variant whenever hnRNP proteins
bound to variable exon 7 can form a complex with promoter-bound IRF-1 [95].
IFN-γ and interleukin (IL)-1b also led to important changes in alternative splicing in pancreaticβ cells
by modulating splicing in about 20% of all expressed genes [96]. Similarly, IL-6 or granulocyte-macrophage
colony stimulating factor (GM-CSF) modulated alternative splicing of BCL2L1 in K562 leukemia
cells towards its anti-apoptotic splice variant BCL-x(L). Both cytokines required different intronic
sequences for their responses, but the underlying molecular mechanisms remained unclear [97]. It was
undetermined as to which mechanism is used by cytokines to induce the observed alternative splicing
of induced nitric oxide synthase (iNOS) in D-lactate dehydrogenase (DLD1) and A549 tumor cells [98].
It is interesting to note that the use of non-steroidal anti-inflammatory drugs can also influence
alternative splicing. Treatment of colon cancer cells with ibuprofen, for example, led to inhibition of
tumor-related RAC1b [99] and this involved reduced phosphorylation of SRSF1, which is required for
inclusion of the alternative exon [100].
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3.2. Metabolic Stress Conditions
Tumor cells respond to adverse conditions with the activation of stress signaling pathways and
adapt their gene expression program, including changes in alternative splicing.
3.2.1. Hypoxia
Cancer cells are often confronted with a significant reduction in oxygen availability, which is a
major factor of selective pressure on tumor cell survival. Hypoxic regions have been identified within
all solid tumors and their presence has been linked to malignant progression, metastasis, resistance to
therapy, and poor clinical outcomes following treatment. Cellular responses to hypoxia are mediated
by hypoxia inducible transcription factors (HIFs) [101]. In hepatocellular carcinoma cells, cultivated
under hypoxia-mimicking conditions, exon array analysis showed 3059 alternative splicing events in
2005 genes [102]. The HIF activation can act through increased expression of CLK1 kinase leading to
global hyperphosphorylation of SR proteins and the activation of hypoxia-dependent splice sites in
HeLa cells [103].
3.2.2. Oxidative Stress
Excessive generation of reactive oxygen species (ROS) in the body interferes with signaling
pathways and is involved in several pathological conditions including cancer [104]. In a human gastric
cancer cell line (AGS), oxidative stress led to phosphorylation and translocation of splicing factor
TRA2B from the nucleus to the cytoplasm. In consequence, alternative splicing of several variable
exons in the invasiveness-related CD44 gene was observed [105].
3.2.3. Osmotic Stress
Stress signals emanating from osmotic shock activate the p38-MAPK pathway via upstream
kinases mitogen-activated protein kinase (MKK3/6). Activation of the p38-MAPK pathway, but
not mitogenic stimulation, induces hnRNPA1 phosphorylation in the nucleus and then export into
the cytoplasm [106–108]. The stress-induced decrease in nuclear hnRNPA1 abundance changed the
alternative splicing pattern of an adenovirus E1A pre-mRNA splicing reporter and is expected to affect
many endogenous alternative splicing events. Another effect observed under osmotic stress is the
translocation of SRPK1 to the nucleus following differential association with heat shock proteins [84],
which suggests that stress signaling also triggered differential phosphorylation of SR proteins besides
affecting cytoplasmic translocation of hnRNPA1.
3.2.4. Genotoxic Stress
DNA damage leads to genotoxic stress and can be caused by ROS, alkylating chemicals, irradiation
or certain anti-cancer drugs. Following ultra violet (UV) irradiation or cisplatin treatment, for example,
the stress-inducible alternative splice forms of mouse double minute 2 homolog (MDM2), MDM2-ALT1
and MDMX-ALT2, lack the p53-binding domain, and were detected in breast cancer cells as important
modifiers of the p53-mediated cellular stress response [109].
Cisplatin treatment also led to phosphorylation of splicing factor SRSF2 but prevented
its acetylation, a novel post-translational modification leading to SRSF2 protein accumulation.
The acetyltransferase Tip60 acetylates SRSF2 on lysine 52 within the RNA recognition motif, and
this triggered proteasomal degradation, whereas deacetylase histone deacetylase 6 (HDAC6) reversed
acetylation as a positive regulator of SRSF2 protein levels. In addition, Tip60 inhibited SRSF2
phosphorylation by modulating the nuclear translocation of both SRPK1 and SRPK2 kinases. As a target
transcript in response to cisplatin treatment, alternative splicing of an anti-apoptotic caspase-8 variant
was identified that determined whether cells underwent apoptosis or G2/M cell cycle arrest [110,111].
Recently, a pathway linking DNA damage repair to the control of alternative splicing regulation
was defined in keratinocytes. Ultra-violet irradiation induces cyclobutane pyrimidine dimers and the
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nucleotide excision repair pathway activates the protein kinase ATR, which promotes RNA polymerase
II hyperphosphorylation. This modification decreased the elongation rate of transcription, which then
allows time for the binding of lower-affinity splicing regulators and results in alternative splicing,
in this case, in a group of 170 genes involved in defining cell survival, cell cycle progression or
DNA repair [112].
3.3. Extracellular Matrix-Derived Signals
The extracellular matrix (ECM) has an important structural support function for cells but is
not a static entity. Tumor cells or stromal cell types including fibroblasts can modulate the ECM in
response to wounding, inflammation or cancer cell-derived stimuli. Changes in matrix composition,
3D-organization or matrix stiffness communicate with a diversity of cell surface receptors [113,114]
and result in a signaling response [115], including changes in alternative splicing.
In mammary epithelial cells, a laminin-rich basement membrane activated mostly α6β4 integrin
receptors that stimulate c-Jun N-terminal kinase (JNK) signaling. As a result, alternative splicing
of the fibronectin gene at the ED-I and ED-III regions is inhibited [116]. By contrast, on stiff ECM
substrates, β1-containing integrin complexes stimulate PI3K-AKT signaling, leading to the activation
of the SR proteins that promote the inclusion of the cell cycle promoting ED-I exon region [117].
In parallel, this pathway affected further splicing events, leading to the production of PKC βII and the
anti-angiogenic VEGF165b splice variants. Thus, depending on the ECM composition and the type of
integrins activated, different intracellular signaling pathways mediate antagonistic splicing decisions.
Finally, remodeling the ECM through experimental activation of extracellular matrix
metalloproteinase 3 (MMP-3) in mouse mammary epithelial cells induced the expression of splice
variant RAC1b, primarily through release of the repressor hnRNPA1 from the alternative exon [118].
In these cells, RAC1b caused an increase in cellular ROS and stimulated the expression of the
transcription factor Snail, which induced epithelial-mesenchymal transition [119].
4. Concluding Remarks
Aberrant profiles observed in tumors mostly reflect the selection of endogenous alternative
splicing variants with different functional properties that allow the malignant progression of initiated
tumor cells and thus contribute specifically to tumor progression.
Figure 1 schematically summarizes the mechanisms by which deregulated cancer cell signaling
affects the molecular decisions of the splicing machinery. Much remains to be learned about these
mechanisms, but also to what extent mutational events that promote the generation of certain
alternative splicing variants may shape cancer cell signaling.
In this respect, the study of individual splicing variants is important for several reasons: it helps
with understanding of the basic principles underlying splicing regulation, and is an opportunity to
identify variant proteins as novel biomarkers, or even therapeutic targets in specific tumor types.
Examples for therapeutic options are the development of small molecule inhibitors that target the
function or activity of a tumor-promoting variant, or the downregulation of its expression using
RNA interference strategies or splice-switching anti-sense oligonucleotides. In addition, spliceosome
inhibitory drugs such as Spliceostatin A or Sudemycins, which target the U2 snRNP component
SF3B1 [120], revealed some tumor cell specific cytotoxic effects in leukemia that were associated with
specific changes in alternative splicing [121]. However, it will be important to move our understanding
from individual splicing variants to the overall pattern of alternative splicing observed in a given
cancer cell. The reason is that whenever a splicing factor suffers changes in its expression level, activity,
or subcellular location, then a plethora of splicing decisions in many different genes will be affected in
the same cell. In the case of SRSF1, for example, its selective depletion in cells was reported to affect
498 splicing events [122].
In addition, fine-tuning of alternative splicing patterns arises from a combinatorial mode of
splicing regulation, based on competition or collaboration between different splicing factors or
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RNA-binding proteins. The complexity in understanding fine-tuning is reflected by the fact that
bioinformatic work identified 254 proteins in the human genome with experimental evidence for their
involvement in splicing [123]. In addition, a more recent biochemical approach identified 860 proteins
in HeLa cells that are able to bind RNA, including over 300 proteins not previously recognized
as RNA-binding [124]. Integrating this information with cell signaling events into a network of
functionally relevant changes in a given gene expression program is a current major challenge.
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